




Instance: composition-en-3fb39d4138ab0b1b436f7dc265a1c128
InstanceOf: CompositionUvEpi
Title: "Composition for optruma Package Leaflet"
Description:  "Composition for optruma Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7dd7043ea9dd32e62f35d29ae9722c9c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - optruma"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Optruma is and what it is used for </li>
<li>What you need to know before you take Optruma </li>
<li>How to take Optruma </li>
<li>Possible side effects </li>
<li>How to store Optruma </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What optruma is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What optruma is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Optruma contains the active substance raloxifene hydrochloride. </p>
<p>Optruma is used to treat and prevent osteoporosis in postmenopausal women. Optruma reduces the 
risk of vertebral fractures in women with postmenopausal osteoporosis. A reduction in the risk of hip 
fractures has not been shown. </p>
<p>How Optruma works </p>
<p>Optruma belongs to a group of non-hormonal medicines called Selective Oestrogen Receptor 
Modulators (SERMs). When a woman reaches the menopause, the level of the female sex hormone 
oestrogen goes down. Optruma mimics some of the helpful effects of oestrogen after the menopause.  </p>
<p>Osteoporosis is a disease that causes your bones to become thin and fragile - this disease is especially 
common in women after the menopause. Although it may have no symptoms at first, osteoporosis 
makes you more likely to break bones, especially in your spine, hips and wrists and may cause back 
pain, loss of height and a curved back. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take optruma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take optruma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Optruma: </p>
<ul>
<li>If you are being treated or have been treated for blood clots in the legs (deep vein thrombosis), 
in the lungs (pulmonary embolism) or in the eyes (retinal vein thrombosis). </li>
<li>If you are allergic (hypersensitive) to raloxifene or any of the other ingredients of this medicine 
(listed in section 6). </li>
<li>If there is still a possibility that you can get pregnant, Optruma could harm your unborn child. </li>
<li>If you have liver disease (examples of liver disease include cirrhosis, mild hepatic impairment 
or cholestatic jaundice). </li>
<li>If you have severe kidney problems. </li>
<li>If you have any unexplained vaginal bleeding. This must be investigated by your doctor. </li>
<li>If you have active uterine cancer, as there is insufficient experience of Optruma use in women 
with this disease. </li>
</ul>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before you take Optruma. </p>
<ul>
<li>If you are immobilised for some time such as being wheel-chair bound, needing to be admitted 
to a hospital or having to stay in bed while recovering from an operation or an unexpected 
illness as these may increase your risk of blood clots (deep vein thrombosis, pulmonary 
embolism or retinal vein thrombosis). </li>
<li>If you have had a cerebrovascular accident (e.g. stroke), or if your doctor has told you that you 
are at high risk of having one. </li>
<li>If you have liver disease </li>
<li>If you are suffering from breast cancer, as there is insufficient experience of Optruma use in 
women with this disease. </li>
<li>If you are receiving oral oestrogen therapy. </li>
</ul>
<p>It is unlikely that Optruma will cause vaginal bleeding. So any vaginal bleeding while you take 
Optruma is unexpected. You should have this investigated by your doctor. </p>
<p>Optruma does not treat postmenopausal symptoms, such as hot flushes. </p>
<p>Optruma lowers total cholesterol and LDL ("bad") cholesterol. In general, it does not change 
triglycerides or HDL ("good") cholesterol. However, if you have taken oestrogen in the past and had 
extreme elevations in triglycerides, you should talk to your doctor before taking Optruma.   </p>
<p>Optruma contains lactose 
If you have been told by your doctor that you have an intolerance to lactose, a type of sugar, contact 
your doctor before taking this medicinal product. </p>
<p>Other medicines and Optruma<br />
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, including medicines obtained without a prescription. </p>
<p>If you are taking digitalis medicines for your heart or anticoagulants like warfarin to thin your blood, 
your doctor may need to adjust your dose of these medicines. </p>
<p>Tell your doctor if you are taking cholestyramine which is mainly used as lipid-lowering medicine, 
because Optruma may not work as well. </p>
<p>Pregnancy and breast-feeding<br />
Optruma is for use only by postmenopausal women and must not be taken by women who could still 
have a baby. Optruma could harm your unborn child. 
Do not take Optruma if you are breast-feeding as it might be excreted in mother's milk. </p>
<p>Driving and using machines 
Optruma has no or negligible effects on driving or using machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take optruma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take optruma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or 
pharmacist if you are not sure. </p>
<p>The dose is one tablet a day. It does not matter what time of day you take your tablet but taking the 
tablet at the same time each day will help you remember to take it. You may take it with or without 
food. 
The tablets are for oral use. 
Swallow the tablet whole. If you wish you may take a glass of water with it. Do not break or crush the 
tablet before taking it. A broken or crushed tablet may taste bad and there is a possibility that you will 
receive an incorrect dose. </p>
<p>Your doctor will tell you how long you should continue to take Optruma. The doctor may also advise 
you to take calcium and vitamin D supplements. </p>
<p>If you take more Optruma than you should 
Tell your doctor or pharmacist. If you take more Optruma than you should you could have leg cramps 
and dizziness. </p>
<p>If you forget to take Optruma 
Take a tablet as soon as you remember and then continue as before. Do not take a double dose to make 
up for a forgotten tablet dose. </p>
<p>If you stop taking Optruma 
You should talk to your doctor first. 
It is important that you continue taking Optruma for as long as your doctor prescribes the medicine, 
Optruma can treat or prevent your osteoporosis only if you continue to take the tablets. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects although not everybody gets them. The 
majority of side effects seen with Optruma have been mild. </p>
<p>The most common side effects (affects more than 1 user in 10) are:<br />
* Hot flushes (vasodilatation) 
* Flu syndrome 
* Gastrointestinal symptoms such as nausea, vomiting, abdominal pain and stomach upset 
* Increased blood pressure </p>
<p>Common side effects (affects 1 to 10 users in 100) are: 
* Headache including migraine 
* Leg cramps<br />
<em> Swelling of hands, feet and legs (peripheral oedema)<br />
</em> Gallstones 
* Rash 
* Mild breast symptoms such as pain, enlargement and tenderness </p>
<p>Uncommon side effects (affects 1 to 10 users in 1000) are: 
* Increased risk of blood clots in the legs (deep vein thrombosis) 
* Increased risk of blood clots in the lungs (pulmonary embolism) 
* Increased risk of blood clots in the eyes (retinal vein thrombosis) 
* Skin around the vein is red and painful (superficial vein thrombophlebitis) 
* Blood clot in an artery (for example stroke, including an increased risk of dying from stroke)<br />
* Decrease in the number of the platelets in the blood  </p>
<p>In rare cases, blood levels of liver enzymes may increase during treatment with Optruma.  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store optruma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store optruma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use after the expiry date which is stated on the pack after EXP. The expiry date refers to the 
last day of the month.  </p>
<p>Store in the original package. Do not freeze.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Optruma contains 
- The active substance is raloxifene hydrochloride. Each tablet contains 60 mg of raloxifene 
hydrochloride, which is equivalent to 56 mg raloxifene. </p>
<ul>
<li>The other ingredients  are: </li>
</ul>
<p>Tablet Core: Povidone, polysorbate 80, lactose, lactose monohydrate, crospovidone, magnesium 
stearate.<br />
Tablet coating: Titanium dioxide (E 171), polysorbate 80, hypromellose, macrogol 400, carnauba wax.<br />
Ink: Shellac, propylene glycol, indigo carmine (E 132). </p>
<p>What Optruma looks like and contents of the pack 
Optruma are white, oval, film coated tablets which are marked with the number 4165. They are packed 
in blisters or in plastic bottles. The blister boxes contain 14, 28 or 84 tablets. The bottles contain tablets. Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands  </p>
<p>Manufacturer 
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spain. </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Eli Lilly Benelux S.A./N.V. 
T l/Tel: + 32-(0)2 548 84 Lietuva 
Eli Lilly Lietuva<br />
Tel. +370 (5) 2649<br />
  "     "  . . - <br />
 . + 359 2 491 41 Luxembourg/Luxemburg 
Eli Lilly Benelux S.A./N.V. 
T l/Tel: + 32-(0)2 548 84  esk  republika 
ELI LILLY  R, s.r.o. 
Tel: + 420 234 664 Magyarorsz g 
Lilly Hung ria Kft. 
Tel: + 36 1 328 5Danmark 
Eli Lilly Danmark A/S 
Tlf: +45 45 26 60 Malta 
Charles de Giorgio Ltd. 
Tel: + 356 25600 Deutschland 
Lilly Deutschland GmbH<br />
Tel. + 49-(0) 6172 273 2Nederland 
Eli Lilly Nederland B.V. 
Tel: + 31-(0) 30 60 25 Eesti 
Eli Lilly Nederland B.V. 
Tel: +372 6 817 Norge 
Eli Lilly Norge A.S. 
Tlf: + 47 22 88 18 <br />
 -   . . . . <br />
 : +30 210 629 4 sterreich 
Eli Lilly Ges.m.b.H.<br />
Tel: + 43-(0) 1 711 Espa a 
Lilly S.A. 
Tel: +34-91-663 50 Polska 
Eli Lilly Polska Sp. z o.o. 
Tel: +48 22 440 33 France 
Pierre Fabre M dicament 
T l: + 33-(0) 1 49 10 80 Portugal 
Lilly Portugal Produtos Farmac uticos, Lda 
Tel: + 351 21412 66 Hrvatska 
Eli Lilly Hrvatska d.o.o. 
Tel: +385 1 2350 Rom nia 
Eli Lilly Rom nia S.R.L. 
Tel: + 40 21 4023Ireland 
Eli Lilly and Company (Ireland) Limited 
Tel: + 353-(0) 1 661 4Slovenija 
Eli Lilly farmacevtska dru ba, d.o.o. 
Tel: +386 (0)1 580 00  sland 
Icepharma hf. 
S mi + 354 540 8Slovensk  republika 
Eli Lilly Slovakia s.r.o. 
Tel: + 421 220 663 Italia 
A. Menarini 
Industrie Farmaceutiche Riunite s.r.l. 
Tel: +39-055 56Suomi/Finland 
Oy Eli Lilly Finland Ab 
Puh/Tel: + 358-(0) 9 85 45 <br />
Phadisco Ltd<br />
 : +357 22 715Sverige 
Eli Lilly Sweden AB 
Tel: + 46-(0) 8 7378Latvija 
Eli Lilly (Suisse) S.A P rst vniec ba Latvij <br />
Tel: +371 67364United Kingdom (Northern Ireland) 
Eli Lilly and Company (Ireland) Limited 
Tel: + 353-(0) 1 661 4This leaflet was last revised in month YYYY. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency (EMA) web 
site: http://www.ema.europa.eu </p>         </div>"""      



Instance: composition-da-3fb39d4138ab0b1b436f7dc265a1c128
InstanceOf: CompositionUvEpi
Title: "Composition for optruma Package Leaflet"
Description:  "Composition for optruma Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7dd7043ea9dd32e62f35d29ae9722c9c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - optruma"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Optruma 
3. Sådan skal De tage Optruma 
4. Bivirkninger<br />
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What optruma is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What optruma is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Optruma indeholder det aktive indholdsstof raloxifenhydrochlorid. </p>
<p>Optruma bruges til at behandle og forebygge knogleskørhed hos kvinder, der har passeret overgangs-
alderen (postmenopausal osteoporose). Optruma nedsætter risikoen for brud på rygsøjlen hos kvinder 
med knogleskørhed efter overgangsalderen. En nedsat risiko for hoftebrud er ikke set. </p>
<p>Virkning </p>
<p>Optruma tilhører en gruppe af ikke-hormonale lægemidler, som kaldes selektive østrogen-receptor 
modulatorer (SERM). Når en kvinde kommer i overgangsalderen, falder produktionen af det 
kvindelige kønshormon, østrogen. Optruma efterligner nogle af de gavnlige virkninger af østrogen 
efter overgangsalderen.  </p>
<p>Knogleskørhed er en sygdom, som gør Deres knogler tynde og skrøbelige. Denne sygdom er især 
almindelig hos kvinder efter overgangsalderen. Selvom knogleskørhed i begyndelsen ikke giver 
symptomer, kan den øge risikoen for, at De brækker Deres knogler, specielt rygsøjlen, hofterne og 
håndleddene. Knogleskørhed kan også medføre, at De får rygsmerter, bliver lavere og får en rund 
ryg. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take optruma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take optruma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Optruma </p>
<ul>
<li>
<p>hvis De bliver eller har været behandlet for blodpropper (blodprop i benene, blodprop i 
lungerne eller blodprop i øjets nethinde). </p>
</li>
<li>
<p>hvis De er allergisk (overfølsom) over for raloxifen eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i punkt 6).  </p>
</li>
<li>
<p>hvis De stadigvæk har mulighed for at blive gravid. Optruma kan skade det ufødte barn. </p>
</li>
<li>
<p>hvis De har en leversygdom (eksempler på leversygdomme omfatter skrumpelever, let nedsat 
leverfunktion og gulsot på grund af afløbshindring). </p>
</li>
<li>
<p>hvis De har svære problemer med nyrerne. </p>
</li>
<li>
<p>hvis De af ukendt årsag har blødning fra underlivet. Dette skal undersøges af Deres læge. </p>
</li>
<li>
<p>hvis De har aktiv livmoderkræft, da der er utilstrækkelig erfaring med Optruma hos kvinder 
med denne sygdom. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apoteketspersonalet, før De tager Optruma  </p>
<ul>
<li>
<p>hvis De ikke kan bevæge Dem normalt i nogen tid, fordi De sidder i kørestol, skal på 
hospitalet eller ligge i sengen efter en operation eller en uventet sygdom, da dette kan øge 
Deres risiko for blodpropper (blodprop i benene, blodprop i lungerne eller blodprop i øjets 
nethinde). </p>
</li>
<li>
<p>Optrumahvis De har haft et slagtilfælde, eller hvis Deres læge har fortalt Dem, at De har høj 
risiko for at få et. </p>
</li>
<li>
<p>hvis De har en leversygdom </p>
</li>
<li>
<p>hvis De har brystkræft, idet der er begrænset erfaring med brug af Optruma hos kvinder med 
denne sygdom. </p>
</li>
<li>
<p>hvis De tager hormontabletter med østrogen. </p>
</li>
</ul>
<p>Det er usandsynligt, at Optruma vil give blødning fra underlivet. Enhver form for blødning fra 
underlivet, mens De tager Optruma, er derfor uventet. De bør have dette undersøgt af Deres læge. </p>
<p>Optruma kan ikke lindre symptomer, såsom hedestigninger, som opstår i forbindelse med overgangs-
alderen. </p>
<p>Optruma sænker det samlede kolesterol og LDL ("farligt") kolesterol. Generelt set påvirker det 
hverken triglycerider eller HDL ("sundt") kolesterol. Hvis De imidlertid tidligere har taget østrogen, 
og De har haft voldsomme stigninger i blodets triglycerider, bør De tale med Deres læge, før De 
tager Optruma.  </p>
<p>Optruma indeholder lactose 
Kontakt lægen, før De tager denne medicin, hvis lægen har fortalt Dem, at De ikke tåler visse 
sukkerarter,  </p>
<p>Brug af anden medicin sammen med Optruma 
Fortæl altid lægen eller apotekspersonalet, hvis De bruger anden medicin eller har gjort det for nylig. 
Dette gælder også medicin, som ikke er købt på recept, f.eks. naturlægemidler, og vitaminer og 
mineraler. </p>
<p>Hvis De tager digitalispræparater på grund af Deres hjerte eller antikoagulantia for at fortynde Deres 
blod (f.eks. warfarin), er Deres læge måske nødt til at justere Deres dosis af denne medicin. </p>
<p>Fortæl det til Deres læge, hvis De får colestyramin, der hovedsageligt anvendes som lipidsænkede 
medicin, da Optruma muligvis ikke virker så godt sammen med colestyramin. </p>
<p>Graviditet og amning 
Optruma må kun anvendes af kvinder, der har passeret overgangsalderen og må ikke anvendes af 
kvinder, der stadig kan få børn. Optruma kunne skade det ufødte barn. 
Anvend ikke Optruma hvis De ammer, da det muligvis udskilles i modermælk. </p>
<p>Trafik- og arbejdssikkerhed 
Optruma påvirker ikke eller kun i ubetydelig grad evnen til at køre bil eller betjene maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take optruma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take optruma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apoteketspersonalet. </p>
<p>Doseringen er én tablet daglig. Det er lige meget, hvornår på dagen De tager din tablet, men hvis De 
tager tabletten på samme tidspunkt hver dag, er det nemmere at huske. De kan tage tabletten med 
eller uden mad. </p>
<p>Tabletterne er til oral anvendelse. 
Synk tabletten hel. De skal synke tabletten med et glas vand eller anden væske. Del eller knus ikke 
tabletten inden indtagelse. En delt eller knust tablet kan smage dårligt, og der er risiko for, at De får 
en forkert dosis. </p>
<p>Deres læge vil fortælle Dem, hvor længe De skal tage Optruma. Deres læge vil måske også råde 
Dem til at tage kalk- eller vitamin D-tilskud. </p>
<p>Hvis De har taget for mange Optruma tabletter<br />
Kontakt lægen eller apoteket.  De kan få kramper i benene eller blive svimmel, hvis De har taget 
flere Optruma tabletter, end De skal. </p>
<p>Hvis De har glemt at tage Optruma<br />
Tag en tablet lige så snart, De husker det, og fortsæt derefter som før. De må ikke tage en 
dobbeltdosis som erstatning for den glemte. </p>
<p>Hvis De holder op med at tage Optruma 
De skal først tale med Deres læge om det. 
Det er vigtigt, at De fortsætter med at tage Optruma i så lang tid, som lægen har ordineret medicinen. 
Optruma kan kun behandle eller forebygge knogleskørhed, hvis De fortsætter med at tage tabletterne. </p>
<p>Spørg lægen eller på apoteket, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. 
Størstedelen af de bivirkninger, som er set med Optruma, har været lette. </p>
<p>Meget almindelig (kan ramme mere end 1 af 10 patienter): </p>
<ul>
<li>
<p>Hedeture </p>
</li>
<li>
<p>Influenzasymptomer </p>
</li>
<li>
<p>Gener fra mave-tarmkanalen såsom kvalme, opkastning, mavesmerter, 
fordøjelsesbesvær </p>
</li>
<li>
<p>Forhøjet blodtryk </p>
</li>
</ul>
<p>Almindelig (kan ramme 1 til 10 ud af 100 patienter): </p>
<ul>
<li>
<p>Hovedpine herunder migræne </p>
</li>
<li>
<p>Kramper i benene </p>
</li>
<li>
<p>Hævede hænder, fødder og ben (perifer væskeophobning): </p>
</li>
<li>
<p>Galdesten </p>
</li>
<li>
<p>Hududslæt </p>
</li>
<li>
<p>Lette symptomer i brystet, såsom smerter, hævelse, ømhed </p>
</li>
</ul>
<p>Ikke almindelig (kan ramme 1 til 10 ud af 1.000 patienter): </p>
<ul>
<li>
<p>Øget risiko for blodpropper i benene (dyb venetrombose) </p>
</li>
<li>
<p>Øget risiko for blodpropper i lungerne (lungeemboli) </p>
</li>
<li>
<p>Øget risiko for blodproper i øjet (nethinde venetrombose) </p>
</li>
<li>
<p>Rød og smertende hud omkring en vene (årebetændelse med blodprop i huden) </p>
</li>
<li>
<p>Blodprop i en arterie (f.eks. slagtilfælde samt en øget risiko for at dø af et slagtilfælde) </p>
</li>
<li>
<p>Færre blodplader i blodet </p>
</li>
</ul>
<p>I sjældne tilfælde kan blodets indhold af leverenzymer stige under behandling med Optruma. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, sygeplejerske eller apoteket. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres 
pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at 
fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store optruma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store optruma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke Optruma efter den udløbsdato, der står på pakningen. Udløbsdatoen er den sidste dag i den 
nævnte måned. </p>
<p>Opbevares i originalemballagen. Må ikke fryses.  </p>
<p>Spørg på apoteket, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Optruma indeholder:</p>
<ul>
<li>
<p>Aktivt stof: raloxifenhydrochlorid. Hver tablet indeholder 60 mg raloxifenhydrochlorid, hvilket 
svarer til 56 mg raloxifen. </p>
</li>
<li>
<p>Øvrige indholdsstoffer:  </p>
</li>
</ul>
<p>Tabletkerne: Povidon, polysorbat 80, lactose, lactosemonohydrat, crospovidon, 
magnesiumstearat. </p>
<p>Tabletovertræk: Titandioxid (E 171), polysorbat 80, hypromellose, macrogol 400, 
carnaubavoks. </p>
<p>Blæk: Shellac, propylenglycol, indigotin I (E 132). </p>
<p>Udseende og pakningsstørrelser 
Optruma er hvide, ovale tabletter med et filmovertræk. Tabletterne er mærket med nummeret 4165. De fås i blisterpakninger eller i tabletglas af plastic. Blisterpakningerne indeholder 14, 28 eller tabletter. Tabletglassene indeholder 100 tabletter. Ikke alle pakningsstørrelser er nødvendigvis 
markedsført. </p>
<p>Indehaveren af markedsføringstilladelsen 
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Holland. </p>
<p>Fremstiller 
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spanien. </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Eli Lilly Benelux S.A./N.V. 
Tél/Tel: + 32-(0)2 548 84 Lietuva 
Eli Lilly Lietuva<br />
Tel. +370 (5) 2649България 
ТП "Ели Лили Недерланд" Б.В. - България 
тел. + 359 2 491 41 Luxembourg/Luxemburg 
Eli Lilly Benelux S.A./N.V. 
Tél/Tel: + 32-(0)2 548 84 Česká republika 
ELI LILLY ČR, s.r.o. 
Tel: + 420 234 664 Magyarország 
Lilly Hungária Kft. 
Tel: + 36 1 328 5Danmark 
Eli Lilly Danmark A/S<br />
Tlf: +45 45 26 60 Malta 
Charles de Giorgio Ltd. 
Tel: + 356 25600 Deutschland 
Lilly Deutschland GmbH<br />
Tel. + 49-(0) 6172 273 2Nederland 
Eli Lilly Nederland B.V.<br />
Tel: + 31-(0) 30 60 25 Eesti 
Eli Lilly Nederland B.V. 
Tel: +372 6 817 280<br />
Norge 
Eli Lilly Norge A.S.<br />
Tlf: + 47 22 88 18 Ελλάδα 
ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. <br />
Τηλ: +30 210 629 4Österreich 
Eli Lilly Ges. m.b.H.<br />
Tel: + 43-(0) 1 711 España 
Lilly S.A. 
Tel: +34-91-663 50 Polska 
Eli Lilly Polska Sp. z o.o. 
Tel: +48 22 440 33 France 
Pierre Fabre Médicament 
Tél: + 33-(0) 1 49 10 80 Portugal 
Lilly Portugal Produtos Farmacêuticos, Lda 
Tel: + 351 21412 66 Hrvatska 
Eli Lilly Hrvatska d.o.o. 
Tel: +385 1 2350 România 
Eli Lilly România S.R.L. 
Tel: + 40 21 4023Ireland 
Eli Lilly and Company (Ireland) Limited.<br />
Tel: + 353-(0) 1 661 4 Slovenija 
Eli Lilly farmacevtska družba, d.o.o. 
Tel: +386 (0)1 580 00 Ísland 
Icepharma hf. 
Sími + 354 540 8Slovenská republika 
Eli Lilly Slovakia, s.r.o. 
Tel: + 421 220 663 Italia 
A. Menarini 
Industrie Farmaceutiche Riunite s.r.l 
Tel: +39-055 56Suomi/Finland 
Oy Eli Lilly Finland Ab<br />
Puh/Tel: + 358-(0) 9 85 45 Κύπρος 
Phadisco Ltd<br />
Τηλ: +357 22 715Sverige 
Eli Lilly Sweden AB 
Tel: + 46-(0) 8 7378Latvija 
Eli Lilly (Suisse) S.A Pārstāvniecība Latvijā 
Tel: +371 67364United Kingdom (Northern Ireland) 
Eli Lilly and Company (Ireland)Limited 
Tel: + 353-(0) 1 661 4 
Denne indlægsseddel blev senest ændret  </p>
<p>De kan finde yderligere oplysninger om Optruma på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-3fb39d4138ab0b1b436f7dc265a1c128
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for optruma Package Leaflet for language en"
Description: "ePI document Bundle for optruma Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-3fb39d4138ab0b1b436f7dc265a1c128"
* entry[0].resource = composition-en-3fb39d4138ab0b1b436f7dc265a1c128

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3fb39d4138ab0b1b436f7dc265a1c128"
* entry[=].resource = mp3fb39d4138ab0b1b436f7dc265a1c128
                            
                    
Instance: bundlepackageleaflet-da-3fb39d4138ab0b1b436f7dc265a1c128
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for optruma Package Leaflet for language da"
Description: "ePI document Bundle for optruma Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-3fb39d4138ab0b1b436f7dc265a1c128"
* entry[0].resource = composition-da-3fb39d4138ab0b1b436f7dc265a1c128

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3fb39d4138ab0b1b436f7dc265a1c128"
* entry[=].resource = mp3fb39d4138ab0b1b436f7dc265a1c128
                            
                    



Instance: mp3fb39d4138ab0b1b436f7dc265a1c128
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product optruma"
Description: "optruma"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/98/074/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Optruma is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "optruma"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 3fb39d4138ab0b1b436f7dc265a1c128ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "optruma"

* status = #current
* mode = #working

* title = "List of all ePIs associated with optruma"

* subject = Reference(mp7dd7043ea9dd32e62f35d29ae9722c9c)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#optruma "optruma"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-3fb39d4138ab0b1b436f7dc265a1c128) // optruma en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-3fb39d4138ab0b1b436f7dc265a1c128) // optruma da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-3fb39d4138ab0b1b436f7dc265a1c128
InstanceOf: List

* insert 3fb39d4138ab0b1b436f7dc265a1c128ListRuleset
    